中国新药杂志

多肽类药物在新生儿缺氧缺血性脑损伤中的研究进展

PDF下载

侯雪雯 , 邱洁

中国新药杂志 | 综述 2021,30(2): 139-144

收起

中国新药杂志 |综述 2021 , 30 (2) : 139 -144

多肽类药物在新生儿缺氧缺血性脑损伤中的研究进展

全屏

[Author(id=1322627344901190567, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=houxuewen1123@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322627344980882345, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, authorId=1322627344901190567, language=EN, stringName=Xue-wen HOU, firstName=Xue-wen, middleName=null, lastName=HOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Newborn Infants, Children's Hospital of Nanjing Medical University, Nanjing 210008, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322627345060574122, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, authorId=1322627344901190567, language=CN, stringName=侯雪雯, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学附属儿童医院新生儿医疗中心，南京　210008, bio={"content":"

侯雪雯，女，硕士研究生，研究方向：新生儿脑损伤。E-mail：houxuewen1123@163.com。

"}, bioImg=null, bioContent=

侯雪雯，女，硕士研究生，研究方向：新生儿脑损伤。E-mail：houxuewen1123@163.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322627344796332963, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, xref=null, ext=[AuthorCompanyExt(id=1322627344813110180, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, companyId=1322627344796332963, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Newborn Infants, Children's Hospital of Nanjing Medical University, Nanjing 210008, China), AuthorCompanyExt(id=1322627344825693093, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, companyId=1322627344796332963, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属儿童医院新生儿医疗中心，南京　210008)])]), Author(id=1322627345127682988, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=qiujie@njmu.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322627348701229998, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, authorId=1322627345127682988, language=EN, stringName=Jie QIU, firstName=Jie, middleName=null, lastName=QIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Newborn Infants, Children's Hospital of Nanjing Medical University, Nanjing 210008, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322627348793504687, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, authorId=1322627345127682988, language=CN, stringName=邱洁, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学附属儿童医院新生儿医疗中心，南京　210008, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322627344796332963, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, xref=null, ext=[AuthorCompanyExt(id=1322627344813110180, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, companyId=1322627344796332963, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Newborn Infants, Children's Hospital of Nanjing Medical University, Nanjing 210008, China), AuthorCompanyExt(id=1322627344825693093, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627344129438624, companyId=1322627344796332963, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属儿童医院新生儿医疗中心，南京　210008)])])]

侯雪雯, 邱洁

作者信息

南京医科大学附属儿童医院新生儿医疗中心，南京　210008

通讯作者:

邱洁，女，副教授，硕士生导师，研究方向：新生儿脑损伤。E-mail：qiujie@njmu.edu.cn。

作者简介:

侯雪雯，女，硕士研究生，研究方向：新生儿脑损伤。E-mail：houxuewen1123@163.com。

Research advances in peptide drugs in treatment of neonatal hypoxic ischemic brain injury

Xue-wen HOU, Jie QIU

Affiliations

Department of Newborn Infants, Children's Hospital of Nanjing Medical University, Nanjing 210008, China

出版时间: 2021-01-30

文章导航

摘要

收起

新生儿缺氧缺血性脑损伤是新生儿死亡和婴幼儿神经系统功能障碍的主要原因，目前唯一公认有效的治疗方法是亚低温治疗。近年来，随着新技术的发展，多肽类药物由于具有高选择性、高效性、耐受性好、制备简单、成本低等优点，得到了广泛关注。利用新生儿缺氧缺血性脑损伤模型的研究发现，多种多肽类药物可直接作用或通过与细胞穿膜肽结合进入神经细胞，通过抑制细胞凋亡、降低神经兴奋性毒性、改善线粒体通透性等机制发挥脑保护作用，作为一种新的新生儿缺氧缺血性脑损伤治疗途径有着巨大的潜力。本文就这些多肽类药物的最新研究进展做一综述，为新生儿缺氧缺血性脑损伤的治疗提供新思路。

关键词

新生儿缺氧缺血性脑损伤 / 多肽 / 细胞穿膜肽 / 脑保护

Abstract

收起

Neonatal hypoxic ischemic brain injury (HIBD) is the main cause of neonatal mortality and neurological dysfunction in infants. Until now, the hypothermia therapy is the only effective treatment of neonatal HIBD. In recent years, with the development of new technologies, peptide drugs have attracted extensive attention due to their advantages including high selectivity, high efficiency, excellent tolerability, simple preparation process and low cost. Using neonatal HIBD models, it was revealed that many kinds of peptide drugs could enter neurocytes directly or through combining with cell penetrating peptides and play roles of brain protection through inhibiting apoptosis, reducing excitotoxicity, improving mitochondrial permeability and so on. Peptide drugs may become new therapeutic approaches of neonatal HIBD. This article reviews the latest research advances in these peptide drugs and provides a new idea for the treatment of neonatal HIBD.

Key words

neonatal hypoxic ischemic brain injury / peptides / cell penetrating peptides / brain protection

引用本文

侯雪雯, 邱洁. 多肽类药物在新生儿缺氧缺血性脑损伤中的研究进展. 中国新药杂志, 2021 , 30 (2) : 139 -144 .

Xue-wen HOU, Jie QIU. Research advances in peptide drugs in treatment of neonatal hypoxic ischemic brain injury[J]. Chinese Journal of New Drugs, 2021 , 30 (2) : 139 -144 .

基金

收起

国家自然科学基金资助项目(81671500)
江苏省临床医学科技专项(BL2012018)
江苏省第十四批“六大人才高峰”高层次人才(WSN-157)
江苏省第五期“333工程”
“十三五”南京市卫生青年人才工程(QRX17076)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

YILDIZ EP, EKICI B, TATLI B. Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment[J]. Expert Rev Neurother, 2017, 17(5): 449-459.

[2]

ZHU M, LU M, LI QJ, et al. Hyperbaric oxygen suppresses hypoxic-ischemic brain damage in newborn rats[J]. J Child Neurol, 2015, 30(1): 75-82.

[3]

WU YW, MATHUR AM, CHANG T, et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II Trial[J]. Pediatrics, 2016, 137(6): e20160191.

[4]

DING H, ZHANG H, DING H, et al. Transplantation of placenta-derived mesenchymal stem cells reduces hypoxic-ischemic brain damage in rats by ameliorating the inflammatory response[J]. Cell Mol Immunol, 2017, 14(8): 693-701.

[5]

王克全, 徐寒梅. 多肽类药物的研究进展[J]. 药学进展, 2015, 39(9): 642-650.

[6]

FOSGERAU K, HOFFMANN T. Peptide therapeutics: current status and future directions[J]. Drug Discov Today, 2018, 20(1): 122-128.

[7]

LAU JL, DUNN MK. Therapeutic peptides: historical perspectives, current development trends, and future directions[J]. Bioorg Med Chem, 2018, 26(10): 2700-2707.

[8]

RAMSEY JD, FLYNN NH. Cell-penetrating peptides transport therapeutics into cells[J]. Pharmacol Ther, 2015, 154: 78-86.

[9]

DERAKHSHANKHAH H, JAFARI S. Cell penetrating peptides: a concise review with emphasis on biomedical applications[J]. Biomed Pharmacother, 2018, 108: 1090-1096.

[10]

MELONI BP, MILANI D, EDWARDS AB, et al. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties[J]. Pharmacol Ther, 2015, 153: 36-54.

[11]

ZHANG Q, LENARDO MJ, BALTIMORE D. 30 Years of NF-κB: a blossoming of relevance to human pathobiology[J]. Cell, 2017, 168(1-2): 37-57.

[12]

LI M, SONG S, LI S, et al. The blockade of NF-κB activation by a specific inhibitory peptide has a strong neuroprotective role in a Sprague-Dawley rat kernicterus model[J]. J Biol Chem, 2015, 290(50): 30042-30052.

[13]

NIJBOER CH, HEIJNEN CJ, GROENENDAAL F, et al. Strong neuroprotection by inhibition of NF-kappaB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines[J]. Stroke, 2008, 39(7): 2129-2137.

[14]

YANG D, SUN YY, LIN X, et al. Intranasal delivery of cell-penetrating anti-NF-κB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury[J]. Exp Neurol, 2013, 247: 447-455.

[15]

LIU Z, WILD C, DING Y, et al. BH4 domain of Bcl-2 as a novel target for cancer therapy[J]. Drug Discov Today, 2016, 21(6): 989-996.

[16]

SUGIOKA R, SHIMIZU S, FUNATSU T, et al. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo[J]. Oncogene, 2003, 22(52): 8432-8440.

[17]

DONNINI S, SOLITO R, MONTI M, et al. Prevention of ischemic brain injury by treatment with the membrane penetrating apoptosis inhibitor, TAT-BH4[J]. Cell Cycle, 2009, 8(8): 1271-1278.

[18]

LI W, ALLEN ME, RUI Y, et al. p39 is responsible for increasing Cdk5 activity during postnatal neuron differentiation and governs neuronal network formation and epileptic responses[J]. J Neurosci, 2016, 36(44): 11283-11294.

[19]

ZEB A, SON M, YOON S, et al. Computational simulations identified two candidate inhibitors of Cdk5/p25 to abrogate tau-associated neurological disorders[J]. Comput Struct Biotechnol J, 2019, 17: 579-590.

[20]

BINUKUMAR BK, PELECH SL, SUTTER C, et al. Profiling of p5, a 24 amino acid inhibitory peptide derived from the CDK5 activator, p35 CDKR1 against 70 protein kinases[J]. J Alzheimers Dis, 2016, 54(2): 525-533.

[21]

TAN X, CHEN Y, LI J, et al. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats[J]. Neuroscience, 2015, 290: 552-560.

[22]

WU QJ, TYMIANSKI M. Targeting NMDA receptors in stroke: new hope in neuroprotection[J]. Mol Brain, 2018, 11(1): 15.

[23]

CHEN Y, BRENNAN-MINNELLA AM, SHETH S, et al. Tat-NR2B9c prevents excitotoxic neuronal superoxide production[J]. J Cereb Blood Flow Metab, 2015, 35(5): 739-742.

[24]

BALLARIN B, TYMIANSKI M. Discovery and development of NA-1 for the treatment of acute ischemic stroke[J]. Acta Pharmacol Sin, 2018, 39(5): 661-668.

[25]

朱志颖, 秦亚娟, 厉廷有. PDZ结构域有望成为新药靶点[J]. 中国新药杂志, 2019, 28(11): 1325-1329.

[26]

XU B, XIAO AJ, CHEN W, et al. Neuroprotective effects of a PSD-95 inhibitor in neonatal hypoxic-ischemic brain injury[J]. Mol Neurobiol, 2016, 53(9): 5962-5970.

[27]

ZHENG J, DAI Q, HAN K, et al. JNK-IN-8, a c-Jun N-terminal kinase inhibitor, improves functional recovery through suppressing neuroinflammation in ischemic stroke[J]. J Cell Physiol, 2020, 235(3): 2792-2799.

[28]

SHVEDOVA M, ANFINOGENOVA Y, ATOCHINA-VASSERMAN EN, et al. c-Jun N-terminal kinases (JNKs) in nyocardial and cerebral ischemia/reperfusion injury[J]. Front Pharmacol, 2018, 9: 715.

[29]

NIJBOER CH, VAN DER KOOIJ MA, VAN BEL F, et al. Inhibition of the JNK/AP-1 pathway reduces neuronal death and improves behavioral outcome after neonatal hypoxic-ischemic brain injury[J]. Brain Behav Immun, 2010, 24(5): 812-821.

[30]

NIJBOER CH, BONESTROO HJ, ZIJLSTRA J, et al. Mitochondrial JNK phosphorylation as a novel therapeutic target to inhibit neuroinflammation and apoptosis after neonatal ischemic brain damage[J]. Neurobiol Dis, 2013, 54: 432-444.

[31]

GRUNWALD J, REJTAR T, SAWANT R, et al. TAT peptide and its conjugates: proteolytic stability[J]. Bioconjug Chem, 2009, 20(8): 1531-1537.

[32]

MADUNA T, LELIEVRE V. Neuropeptides shaping the central nervous system development: Spatiotemporal actions of VIP and PACAP through complementary signaling pathways[J]. J Neurosci Res, 2016, 94(12): 1472-1487.

[33]

GOZES I, DIVINSKY I, PILZER I, et al. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division[J]. J Mol Neurosci, 2003, 20(3): 315-322.

[34]

KUMRAL A, YESILIRMAK DC, SONMEZ U, et al. Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxic-ischemic brain injury in neonatal rats[J]. Brain Res, 2006, 1115(1): 169-178.

[35]

GOZES I, MORIMOTO BH, TIONG J, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)[J]. CNS Drug Rev, 2005, 11(4): 353-368.

[36]

YANASHIMA K, CHIEOSILAPATHAM P, YOSHIMOTO E, et al. Innate defense regulator IDR-1018 activates human mast cells through G protein-, phospholipase C-, MAPK- and NF-κB-sensitive pathways[J]. Immunol Res, 2017, 65(4): 920-931.

[37]

WUERTH KC, FALSAFI R, HANCOCK REW. Synthetic host defense peptide IDR-1002 reduces inflammation in Pseudomonas aeruginosa lung infection[J]. PLoS One, 2017, 12(11): e0187565.

[38]

BOLOURI H, SÄVMAN K, WANG W, et al. Innate defense regulator peptide 1018 protects against perinatal brain injury[J]. Ann Neurol, 2014, 75(3): 395-410.

[39]

HANEY EF, BARBOSA SC, BAQUIR B, et al. Influence of non-natural cationic amino acids on the biological activity profile of innate defense regulator peptides[J]. J Med Chem, 2019, 62(22): 10294-10304.

[40]

THORNTON C, HAGBERG H. Role of mitochondria in apoptotic and necroptotic cell death in the developing brain[J]. Clin Chim Acta, 2015, 451(Pt A): 35-38.

[41]

THORNTON C, LEAW B, MALLARD C, et al. Cell death in the developing brain after hypoxia-ischemia[J]. Front Cell Neurosci, 2017, 11: 248.

[42]

SAWADA M, SUN W, HAYES P, et al. Ku70 suppresses the apoptotic translocation of Bax to mitochondria[J]. Nat Cell Biol, 2003, 5(4): 320-329.

[43]

WANG X, HAN W, DU X, et al. Neuroprotective effect of Bax-inhibiting peptide on neonatal brain injury[J]. Stroke, 2010, 41(9): 2050-2055.

[44]

SUN MY, CUI KJ, YU MM, et al. Bax inhibiting peptide reduces apoptosis in neonatal rat hypoxic-ischemic brain damage[J]. Int J Clin Exp Pathol, 2015, 8(11): 14701-14708.

[45]

孙梦雅, 崔凯洁, 王雯雯, 等. Bax-抑制肽对新生鼠缺氧缺血性脑损伤神经细胞凋亡的抑制作用[J]. 中国新生儿科杂志, 2015, 30(5): 372-376.

[46]

单既利, 韩淑臻, 荆汝泉, 等. Bax抑制肽对新生大鼠缺氧缺血性脑损伤的保护作用[J]. 临床儿科杂志, 2014, 32(3): 254-257.

[47]

JENSEN K, WUWONG DJ, WONG S, et al. Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax[J]. Exp Biol Med (Maywood), 2019, 244(8): 621-629.

[48]

MARTÍNEZ-MORENO CG, CALDERÓN-VALLEJO D, HARVEY S, et al. Growth hormone (GH) and gonadotropin-releasing hormone (GnRH) in the central nervous system: a potential neurological combinatory therapy?[J]. Int J Mol Sci, 2018, 19(2): pii: E375.

[49]

BRYWE KG, LEVERIN AL, GUSTAVSSON M, et al. Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation[J]. Endocrinology, 2005, 146(11): 4665-4672.

[50]

GHIGO E, ARVAT E, GIANOTTI L, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man[J]. J Clin Endocrinol Metab, 1994, 78(3): 693-698.

[51]

ROUMI M, MARLEAU S, DU SOUICH P, et al. Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats[J]. Drug Metab Dispos, 2000, 28(1): 44-50.

[52]

MUGHAL A, O'ROURKE ST. Vascular effects of apelin: mechanisms and therapeutic potential[J]. Pharmacol Ther, 2018, 190: 139-147.

[53]

GU Q, ZHAI L, FENG X, et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway[J]. Neurochem Int, 2013, 63(6): 535-540.

[54]

JIA ZQ, HOU L, LEGER A, et al. Cardiovascular effects of a PEGylated apelin[J]. Peptides, 2012, 38(1): 181-188.

2021年第30卷第2期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-29
出版时间：2021-01-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-04-20

基金

国家自然科学基金资助项目(81671500)

江苏省临床医学科技专项(BL2012018)

江苏省第十四批“六大人才高峰”高层次人才(WSN-157)

江苏省第五期“333工程”

“十三五”南京市卫生青年人才工程(QRX17076)

作者信息

南京医科大学附属儿童医院新生儿医疗中心，南京　210008

通讯作者:

邱洁，女，副教授，硕士生导师，研究方向：新生儿脑损伤。E-mail：qiujie@njmu.edu.cn。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322627344129438624

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT